AMENDMENTS

Please enter the following rewritten claims:

5. (Amended) The substantially pure peptide of claim 1, wherein the peptide is at least 70% identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.

6. (Amended) The substantially pure peptide of claim 5, wherein the peptide is at least 80% identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.

7. (Amended) The substantially pure peptide of claim 5, wherein the peptide is at least 90% identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.

8. (Amended) The substantially pure peptide of claim 5, wherein the peptide is at least 95% identical to a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.

9. (Amended) The substantially pure peptide of claim 5, wherein the peptide has a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.

21. (Amended) The substantially pure peptide of claim 5, wherein one or more amino acid of the peptides selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10 has been substituted by one or more amino acid having a similar size, charge and/or polarity.

34. (Amended) The immunomodulating composition of claim 33, wherein the fragment binds to at least one molecule selected from the group consisting of HLADR1, DR4, and DR7.

38. (Amended) The composition of claim 34, wherein the substantially pure peptide has a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.

43. (Amended) A method for treating or preventing an immune-mediated disease in a subject having or at risk of having the disease comprising administering to the subject, an effective amount of a substantially pure peptide comprising a fragment of a stress protein that binds to MHC class II molecules in a pharmaceutically acceptable carrier, wherein the peptide modulates an immune response, thereby treating or preventing the disease.

51. (Amended) The method of claim 34, wherein the substantially pure peptide has a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.

53. (Amended) The method of claim 52, wherein the fragment binds to at least one molecule selected from the group consisting of HLADR1, DR4, and DR7.

59. (Amended) The method of claim 52, wherein the substantially pure peptide has a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9 and 10.